Beovu is a drug - administered by injections into the eyes - that is used to treat an eye condition called wet age-related macular degeneration (wet AMD). Just 9 months after Beovu injections were approved by the FDA, it was discovered that Beovu caused some patients to suffer a rare and very serious inflammatory condition in their eyes called retinal vasculitis. Patients who developed this dangerous retina condition as a result of the Beovu injection have suffered severe vision loss and blindness. Until recently, this was not disclosed as a known side effect of Beovu injections.
Beovu is believed to cause serious eye injuries, including vision loss and even blindness. The lawsuits against Novartis will be failure to warn if the injuries occurred before the warning was updated in June 2020. Any individual who suffered vision loss after receiving a Beovu injection before June 2020 has strong grounds for a lawsuit against Novartis. Our law firm is actively seeking new cases from anyone who suffered an adverse response and vision loss from a Beovu eye injection.
Beovu is a very new prescription drug that is given by injection for the treatment of a debilitating eye condition called wet age-related macular degeneration (wet AMD). Wet AMD is a disease that occurs when additional blood vessels form in the macula region of the eyes. When these new blood vessels leak, they result in impaired vision. The active ingredient in Beovu, brolucizumab, works by blocking the growth hormone that causes these blood vessels to leak.
Wet AMD is a relatively common eye condition that can have devastating results if not treated. Over 1 million people in the U.S. have wet AMD and it is the leading cause of legal blindness. Currently, the only effective treatments for wet AMD involve the injection of hormone-blocking drugs like Beovu. Beovu was just recently released in October 2019. Beovu was hailed as a major breakthrough in the treatment of wet AMD because it required far fewer injections than the leading alternative (Eylea).Beovu Causes Vision Loss and Blindness in Certain Patients
When Beovu was first approved by the FDA and released in the U.S. in October 2019, there was no warning about potentially serious side-effects. Novartis actively marketed the "proven safety" of its Beovu injections. Within just a few months after the initial release of Beovu, however, reports began streaming into the FDA (and other organizations) about patients having very serious adverse reactions to Beovu. In a certain percentage of patients, the Beovu injections were triggering a dangerous inflammatory response in the retina.
Patients who suffered this reaction to Beovu were eventually diagnosed with retinal vasculitis or retinal vascular occlusion. Retinal vasculitis and retinal vascular occlusion are rare but very serious disorders that involve restricted blood flow to the eyes. Both conditions result in permanent vision loss or total blindness.FDA Required a "Black Box" Warning Label for Beovu
The incoming reports of adverse reactions following the release of Beovu prompted the FDA to conduct a drug safety review. Novartis also launched an internal safety review of the drug. These reviews seemed to confirm that Beovu was the apparent cause of the adverse reactions in some patients that led to retinal vasculitis and retinal vascular occlusion.
In June 2020, the FDA approved a new "black box" warning label for Beovu (the highest risk warning label). The new warning label for Beovu discloses the potential risk of retinal vasculitis and retinal vascular occlusion in some patients. To date, there are no plans for a voluntary or mandatory recall of Beovu. However, the safety concerns about the drug have effectively halted its use.Beovu Eye Damage Lawsuits
When Novartis originally released Beovu on the market the warning label did not disclose anything about the risk of retinal vasculitis and retinal vascular occlusion. This means that Novartis can be held legally liable for any injuries caused by these undisclosed side effects of the drug before the warning label was changed.
A wave of Beovu lawsuits against Novartis is expected in the wake of these developments. Anyone who received Beovu injections and subsequently experienced vision impairment, blindness, or other adverse reactions could potentially have a lawsuit against Novartis. Injuries and reactions potentially linked to Beovu could include:
- retinal vasculitis
- retinal vascular occlusion
- inflammation of the retina
- vision loss
At this point, Beovu vision damage and blindness lawsuits are just starting to get filed against Novartis. So, certainly on some level, it is too soon to speculate about the potential settlement value of Beovu vision damage claims by looking at settlement amounts in prior cases with comparable injuries if this litigation goes well. Keep in mind that these are just estimates.
All of the plaintiffs in the Beovu cases will be seeking compensation for some level of vision loss or impairment. Some of them will be alleging total blindness and others will have only partial vision loss. Based on settlements in prior cases involving vision loss or blindness, our lawyers think the Beovu cases could have the following settlement value:
|Vision Loss||Settlement Range|
|80% - 100%||$650,000 - $800,000|
|40% - 80%||$200,000 - $400,000|
|20% - 40%||$50,000 - $100,000|
If you suffered vision loss or blindness after receiving a Beovu injection, our dangerous drug injury lawyers can help get your Beovu lawsuit filed so you can get the financial compensation you deserve. Call our product liability lawyers today at 800-553-8082 or contact us online.